drugset / Trial / NCT03566316

Efficacy/Safety of Telmisartan/Amlodipine/Rosuvastatin in Hypertensive Patients With Hyperlipidemia

NCT03566316

Phase 3 Completed 134 enrolled IlDong Pharmaceutical Co Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

A Randomized, Double-blind, Multi-center Phase III Clinical Trial to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine and Rosuvastatin Co-administration in Hypertensive Patients with Hyperlipidemia

Timeline

Start
2015-11-24
Primary completion
2017-06-16
Completion
2017-06-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 10 mg
Subject Rosuvastatin Small molecule 20 mg
Subject Rosuvastatin Small molecule 80 mg
Comparator Telmisartan Other / unclassified 20 mg
Comparator Telmisartan Other / unclassified 80 mg